

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2018

Consolidated Statement of Cash Flows

Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

| | Millions of yen | | Thousands of US\$ |
|--|---------------------------------|---------------------------------|---------------------------------|
| | Year ended March 31, 2017 | Year ended March 31, 2018 | Year ended March 31, 2018 |
| Cash flows from operating activities | | | |
| Profit before tax | ¥ 74,540 | ¥ 63,922 | \$ 603,037 |
| Depreciation and amortization | 7,821 | 9,213 | 86,912 |
| Impairment losses | 937 | 306 | 2,883 |
| Interest and dividend income | (2,951) | (2,990) | (28,207) |
| Interest expense | 15 | 14 | 134 |
| (Increase) Decrease in inventories | (2,042) | (5,971) | (56,332) |
| (Increase) Decrease in trade and other receivables | (11,195) | (4,333) | (40,873) |
| Increase (Decrease) in trade and other payables | 4,980 | 300 | 2,827 |
| Increase (Decrease) in provisions | 4,731 | 5,611 | 52,931 |
| Increase (Decrease) in retirement benefit liabilities | 389 | 362 | 3,412 |
| Increase (Decrease) in long-term advances received | (538) | (181) | (1,709) |
| Other | 6,292 | (17,138) | (161,679) |
| Subtotal | 82,978 | 49,114 | 463,337 |
| Interest received | 154 | 95 | 896 |
| Dividends received | 2,818 | 2,902 | 27,379 |
| Interest paid | (15) | (14) | (134) |
| Income taxes paid | (11,485) | (36,370) | (343,113) |
| Net cash provided by (used in) operating activities | 74,450 | 15,727 | 148,365 |
| Cash flows from investing activities | | | |
| Purchases of property, plant, and equipment | (14,805) | (15,620) | (147,358) |
| Proceeds from sales of property, plant and equipment | 274 | 4,663 | 43,995 |
| Purchases of intangible assets | (9,274) | (14,218) | (134,136) |
| Purchases of investments | (3,240) | (60) | (566) |
| Proceeds from sales and redemption of investments | 28,883 | 21,315 | 201,083 |
| Payments into time deposits | (20,800) | (30,800) | (290,566) |
| Other | 974 | 531 | 5,012 |
| Net cash provided by (used in) investing activities | (17,989) | (34,189) | (322,534) |
| Cash flows from financing activities | | | |
| Dividends paid to owners of the parent company | (20,116) | (23,414) | (220,890) |
| Dividends paid to non-controlling interests | (3) | (3) | (29) |
| Repayments of long-term borrowings | (398) | (417) | (3,932) |
| Net increase (decrease) in short-term borrowings | (11) | 58 | 548 |
| Purchases of treasury shares | (22) | (38,773) | (365,779) |
| Net cash provided by (used in) financing activities | (20,552) | (62,549) | (590,082) |
| Net increase (decrease) in cash and cash equivalents | 35,909 | (81,011) | (764,251) |
| Cash and cash equivalents at the beginning of the period | 110,485 | 146,323 | 1,380,410 |
| Effects of exchange rate changes on cash and cash equivalents | (71) | (40) | (379) |
| Cash and cash equivalents at the end of the period | ¥ 146,323 | ¥ 65,273 | \$ 615,781 |